News | April 11, 2025
Granules India completes acquisition of Senn Chemicals
Strengthening capabilities in Peptide Therapeutics and CDMO services
Strengthening capabilities in Peptide Therapeutics and CDMO services
USFDA inspection at Alembic Pharma's Bioequivalence facility
This achievement underscores the company’s steadfast commitment to sustainability, corporate responsibility, and ESG excellence
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
This collaboration aims to bridge modern scientific research with traditional Ayurvedic wisdom, fostering innovative solutions that support holistic well-being
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
Total Income in Q2 FY25 stood at Rs. 532.18 crore
Construction of the plant will commence in 2025 with first production expected to be in 2027
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
Subscribe To Our Newsletter & Stay Updated
